Scorr-Insert
X

Find Oncology Drugs in Phase I Clinical Development in SWITZERLAND

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): FAZ053

            Therapeutic Area: Oncology

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Laekna Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement March 24, 2020

            Details:

            Laekna now has exclusive rights to develop and commercialize the PD-L1 oncology asset. With this move, the company aims to advance clinical research and introduce pioneering new drugs to patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Debio 0123

            Therapeutic Area: Oncology

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 05, 2020

            Details:

            Debio 0123 starts first-in-human, dose escalation phase I clinical trial assessing the safety and efficacy of the compound in combination with carboplatin to treat refractory solid tumors.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IOA-244

            Therapeutic Area: Oncology

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 26, 2020

            Details:

            The phase I study will enrol approximately 60 patients with solid tumours that overexpress PI3K? and are burdened by immune cells of the suppressor phenotype that are sensitive to PI3K? inhibition.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IOA-244

            Therapeutic Area: Oncology

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: INKEF Capital

            Deal Size: $16.5 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing January 23, 2020

            Details:

            iOnctura will use the proceeds of the Series A to move its lead molecule IOA-244, a highly selective PI3K?-inhibitor, into a Phase I trial in solid tumours and its second program, IOA-289, an ATX-inhibitor, through IND enabling studies.